

October 15, 2018



Avalon GloboCare Announces Grand Opening of Newly Renovated Headquarters in New Jersey

FREEHOLD, N.J., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (OTCQB: AVCO), a leading global developer of cell-based technologies and therapeutics, announced today the grand opening of their newly renovated Avalon Executive Center, a three story property located at 4400 Highway 9 in Freehold, New Jersey. The property, a 64,000 square foot class A office building, is Avalon GloboCare's worldwide headquarters.



Lobby of Worldwide Headquarters of Avalon GloboCare Corp.



Worldwide Headquarters of Avalon GloboCare Corp.



Worldwide Headquarters of Avalon GloboCare Corp.

David Jin, M.D., Ph.D., President and CEO of Avalon GloboCare, stated, “We purchased this property a year ago and we are thrilled with how the renovations came out. This state-of-the-art facility is a valuable asset to Avalon as it is geographically centered making our company accessible to New York, New Jersey and Pennsylvania based healthcare

providers, hospitals, pharmaceutical firms and major university research centers. As we continue to make steady progress in the US with top ranked hospitals, like Weill Cornell, we believe our new headquarters will serve as a hub to shape the future of cell-based therapies and regenerative medicine.”

About Avalon GloboCare Corp.

Avalon GloboCare Corp. (OTCQB: AVCO) is a global intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high impact, transformative cell-based /technologies and their clinical applications, as well as healthcare facility management through its core platforms, namely "Avalon Cell" and "Avalon Rehab." In addition, Avalon provides strategic advisory and outsourcing services to facilitate and enhance their clients' growth, development, as well as competitiveness in both domestic and global healthcare markets. Avalon also engages in the management of stem cell banks and specialty clinical laboratories. Through its U.S. subsidiaries, namely GenExosome Technologies Inc. and Avactis Biosciences Inc., Avalon will further establish our leading roles in the fields of CAR-T therapy, liquid biopsy, precision medicine and regenerative medicine.

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (<http://www.sec.gov>). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

Contact Information:

Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com

Investor Relations:

Crescendo Communications, LLC
Tel: (212) 671-1020
avco@crescendo-ir.com

Photos accompanying this announcement are available at
<https://www.globenewswire.com/NewsRoom/AttachmentNg/54e556c6-bf47-4682-a516->

[0f8c6cc0b895](#)

<https://www.globenewswire.com/NewsRoom/AttachmentNg/63574ad0-0726-4545-addd-69f9f67e9436>

<https://www.globenewswire.com/NewsRoom/AttachmentNg/557ccaac-424f-4ee7-80fb-3a0b9684de25>



Source: Avalon GloboCare Corp.